ALK and angioimmunoblastic T-cell lymphoma: A recent nationwide population-based study of 1427 patients in the Netherlands Cancer Registry also demonstrated superior OS outcomes with the use of ASCT in younger patients < 65 years with advanced stage ALK-negative ALCL, AITL or PTCL [17].